Muriel He
ASSOCIATE AT FANGDA PARTNERS Ms. Muriel He specializes in regulatory compliance, general corporate, private equity investment, venture capital and mergers & acquisitions, with a strong track record in various industry sectors such as pharma, life science, healthcare and TMT. Ms. He is routinely representing such multinational corporations as AstraZenca, Novartis, GE, MSD, GSK, Sanofi, Schlumberger, Boehringer Ingelheim, Biogen, Cstone, Assembly, Astellas, Mylan, Siemens, Catalent, Allergan, Hologic, SHIRE, FERRING and Tosh in various legal matters including general corporate, acquisitions and joint venture formation, regulatory compliance, intellectual property and corporate restructure. Ms. He’s experience on product license/collaboration in the life science and …
ASSOCIATE AT FANGDA PARTNERS
Ms. Muriel He specializes in regulatory compliance, general corporate, private equity investment, venture capital and mergers & acquisitions, with a strong track record in various industry sectors such as pharma, life science, healthcare and TMT.
Ms. He is routinely representing such multinational corporations as AstraZenca, Novartis, GE, MSD, GSK, Sanofi, Schlumberger, Boehringer Ingelheim, Biogen, Cstone, Assembly, Astellas, Mylan, Siemens, Catalent, Allergan, Hologic, SHIRE, FERRING and Tosh in various legal matters including general corporate, acquisitions and joint venture formation, regulatory compliance, intellectual property and corporate restructure.
Ms. He’s experience on product license/collaboration in the life science and healthcare areas include: representing AstraZeneca in granting to BioKangtai the exclusive license in China with respect to the AZD1222, an adenovirus vector-based COVID-19 vaccine initially developed by Oxford University, representing Beigene in its granting of exclusive commercialization rights relating to the pipeline (PD-1) monoclonal antibody BGB-A317 to Celgene, represented Boehringer-Ingelheim in its collaboration with Shanghai International Medical Center with respect to Consanas Rehabilitation Center.
See more
Ms. Muriel He specializes in regulatory compliance, general corporate, private equity investment, venture capital and mergers & acquisitions, with a strong track record in various industry sectors such as pharma, life science, healthcare and TMT.
Ms. He is routinely representing such multinational corporations as AstraZenca, Novartis, GE, MSD, GSK, Sanofi, Schlumberger, Boehringer Ingelheim, Biogen, Cstone, Assembly, Astellas, Mylan, Siemens, Catalent, Allergan, Hologic, SHIRE, FERRING and Tosh in various legal matters including general corporate, acquisitions and joint venture formation, regulatory compliance, intellectual property and corporate restructure.
Ms. He’s experience on product license/collaboration in the life science and healthcare areas include: representing AstraZeneca in granting to BioKangtai the exclusive license in China with respect to the AZD1222, an adenovirus vector-based COVID-19 vaccine initially developed by Oxford University, representing Beigene in its granting of exclusive commercialization rights relating to the pipeline (PD-1) monoclonal antibody BGB-A317 to Celgene, represented Boehringer-Ingelheim in its collaboration with Shanghai International Medical Center with respect to Consanas Rehabilitation Center.
